中外製薬株式会社 スポンサーセミナー 特設サイト

Chugai's Strengths in Drug Discovery

Chugai’s drug discovery capabilities are world-class, as illustrated by the five FDA Breakthrough Therapy Designations for three Chugai origin products. In this session, we will introduce our R&D strategy and drug discovery platform with the research history of Chugai’s original projects that recieved breakthrough therapy designation.


Program

Date/Venue

Oct. 11 (Wed.) 15:30 - 16:30
Annex Hall F201

Chugai's Strengths in Drug Discovery

Hisafumi Okabe, Ph.D
Senior Vice President, Chugai Pharmaceutical

 

Broad and precise analyses of the human genome and other approaches are revealing greater details about human disease pathogenesis. These efforts show that the pathophysiology of each patient is different, leading to further segmentation of diseases. (...)

(More)

Drug discovery of small molecule kinase inhibitors: Dicovery of an ALK inhibitor alectinib

Hiroshi Sakamoto, Ph.D
Group manager, Discovery Pharmacology Dept.

 

In the development of anticancer drugs in recent years, personalized medicine that selects optimal therapeutic agents based on genetic information of individual patients is being established, and such molecular targeted drugs are expected to have the maximum efficacy with minimal side effects. Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following genetic alterations of ALK, such as gene fusion, gene amplification, or point mutation. Based on the discovery of the EML4-ALK fusion gene in non-small cell lung cancer (NSCLC) reported in 2007, we have started drug discovery research of ALK inhibitors. (...)

(More)

Continuous innovative drug discovery utilizing antibody engineering technologies

Tomoyuki Igawa, Ph.D
Director, Chief Executive Officer and Research Head, Chugai Pharmabody Research

 

Chugai has developed proprietary antibody engineering technologies and applied them to create projects such as a bispecific antibody mimicking coagulation factor VIII, a long-acting anti-IL6 receptor antibody based on recycling antibody technology, and an anti-IL31 receptor antibody through half-life extension technology. (...)

(More)

*Online pre-registration is required for attending.

Register here.

Chugai Booth Seminars

Please visit the Chugai Pharmaceutical booth C-22 at Bio Japan 2017.
We will hold seminars in English.

Wed. Oct. 11th 
1)11:30〜 2)13:00〜 3)14:30〜
CD3 humanized mouse: Original animal model effective for evaluating T cell redirecting antibodies

Thu. Oct. 12th 
1)11:30〜 2)13:30〜 3)15:30〜
Biotech Manufacturing Capability in Chugai: History, Current Status, and Next Generation

Fri. Oct. 13th 
1)11:30〜 2)13:30〜 3)15:30〜
SKY59, long-acting anti-C5 antibody by recycling technology and Fc engineering technology

Contact:

Business Development Dept.
Chugai Pharmaceutical Co., Ltd.

E-mail: bizdev@chugai-pharm.co.jp

このウィンドウを閉じる

Copyright© 2017 JTB Communication Design, Inc. All rights reserved.